mRNA Technology Newsletter
Issue #23February 9, 20267 studies

Malaria's leftover pigment blocks vaccines—but mRNA fixes it

This week brought major advances in mRNA delivery systems, from cancer vaccines to genetic disease treatments. Researchers are pushing beyond COVID-19 applications to tackle everything from malaria to heart conditions.

🦠 Malaria's leftover pigment blocks vaccines—but mRNA fixes it

  • Scientists discovered that haemozoin (malarial pigment left in the body after blood-stage malaria) impairs how well traditional malaria vaccines work by blocking dendritic cells from taking up antigens

  • When they tested an mRNA vaccine encoding malaria T cell targets in mice previously exposed to Plasmodium, it overcame this blockade and restored protection

  • The combination of traditional radiation-attenuated sporozoites plus mRNA vaccine enhanced liver-resident memory T cells and provided better protection than either approach alone

Why it matters: This explains why malaria vaccines often fail in endemic regions where people have been previously infected, and shows mRNA technology could solve this long-standing problem.

🥇 Top 1% journal 🔗 Nature microbiology 🗓️ Feb 2

Key Findings

🧬 Large lipid nanoparticles with less PEG target immune cells better

  • Researchers created oversized lipid nanoparticles (LLNPs) by reducing PEG content to 0.3% and increasing other components sixfold compared to standard formulations

  • These LLNPs achieved ~82% of GFP-positive cells identified as dendritic cells and ~44% of all dendritic cells expressing the delivered gene

  • In cancer vaccine tests, LLNPs triggered effective tumor regression at doses as low as 1 μg of mRNA

💡 Bigger nanoparticles with optimized surface chemistry could make mRNA cancer vaccines more potent at lower doses.
🥉 Top 5% journal 🔗 J Control Release 🗓️ Feb 4

💊 Gene therapy shows promise for inherited heart disease

  • Scientists used mRNA in lipid nanoparticles to deliver three genes (COL4A3, COL4A4, COL4A5) that produce kidney filtration proteins in mice with Alport syndrome

  • The treatment significantly reduced protein leakage in urine and blood urea nitrogen levels

  • Protection was maintained as long as injections continued, but efficacy was lost when therapy stopped

💡 mRNA therapy could offer hope for genetic kidney diseases, though it appears to require ongoing treatment rather than a permanent cure.

🔬 Low glucose blocks mRNA therapy effectiveness

  • Researchers found that low-glucose conditions significantly reduced mRNA translation into protein in multiple cell types using two different lipid nanoparticle formulations

  • The problem wasn't with cellular uptake or lysosomal escape, but with reduced ATP and GTP levels needed for protein synthesis

  • Mouse tumor models confirmed that hypoglycemia diminished mRNA delivery efficiency in living animals

💡 Cancer patients and stroke victims with low blood sugar may not respond as well to mRNA therapies, suggesting a need for metabolic optimization.
Top 20% journal 🔗 Molecular pharmaceutics 🗓️ Feb 2

🩸 COVID booster changes immune response patterns

  • Analysis of 36 fully vaccinated individuals showed distinct protein profiles in blood plasma after booster vaccination when exposed to SARS-CoV-2 spike protein

  • Post-booster recipients exhibited significant activation of complement cascade, platelet degranulation, and blood coagulation pathways

  • The study identified abundant signatures associated with stress responses and innate immunity that weren't present before the booster

💡 Booster shots may prime the immune system differently than initial vaccines, potentially explaining some post-vaccination reactions.
Top 20% journal 🔗 Journal of proteome research 🗓️ Feb 3

🫁 Liver protein therapy reduces lung scarring

  • Scientists delivered mRNA encoding ornithine transcarbamylase (OTC), a liver enzyme, using lipid nanoparticles in multiple mouse models of liver fibrosis

  • The treatment significantly inhibited collagen deposition and recovered impaired mitochondrial function in hepatocytes

  • When combined with the drug Resmetirom, it showed potent effects against metabolic liver disease with fibrosis

💡 Restoring a single liver enzyme through mRNA therapy could reverse liver scarring, offering hope for patients with advanced liver disease.
🥇 Top 1% journal 🔗 Hepatology (Baltimore, Md.) 🗓️ Feb 3

🧪 Silicone oil from syringes affects mRNA vaccine stability

  • Testing mRNA vaccines stored with silicone oil (used to lubricate prefilled syringes) showed that RNA structure matters for stability

  • Simple poly-A RNA particles grew larger and became less uniform at 25°C with silicone oil, while complex eGFP-mRNA particles remained stable

  • Surprisingly, silicone oil partially protected against light-induced damage, improving transfection efficiency by up to 6-fold in some samples

💡 The type of mRNA and storage conditions both matter for vaccine stability, with some unexpected protective effects from syringe lubricants.
Top 20% journal 🔗 Molecular pharmaceutics 🗓️ Feb 6

Implications

These studies show mRNA technology expanding far beyond COVID vaccines into cancer treatment, genetic diseases, and organ-specific therapies. However, they also reveal important limitations—from glucose dependence to storage challenges—that researchers are actively working to solve.

Studies in this issue

Primary sources used for this newsletter.

  1. mRNA Treatment for Alport Syndrome
    key findingbioRxiv : the preprint server for biology2026-02-06PMID 41648584
  2. Large and low-PEG lipid nanoparticles improve delivery to immune cells for strong mRNA cancer vaccines
    key findingJournal of controlled release : official journal of the Controlled Release Society2026-02-04PMID 41638492
  3. How Low Blood Sugar Affects mRNA Delivery by Fat-Based Nanoparticles and Why
    key findingMolecular pharmaceutics2026-02-02PMID 41627893